Patents by Inventor Simon M. Ametamey

Simon M. Ametamey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
    Patent number: 12180196
    Abstract: The invention relates to a compound of formula (I) wherein A1 and R1-R4 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: December 31, 2024
    Assignees: HOFFMANN-LA ROCHE INC., EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
    Inventors: Simon M. Ametamey, Luca Gobbi, Uwe Grether, Julian Kretz
  • NOVEL PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF CANNABINOID RECEPTOR 2
    Publication number: 20240383872
    Abstract: The invention relates to a compound of formula (I) wherein A1, A2, X and R1—R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: July 26, 2024
    Publication date: November 21, 2024
    Inventors: Luca Gobbi, Uwe Grether, Julian Kretz, Simon M. Ametamey
  • RADIOLABELED CANNABINOID RECEPTOR 2 LIGAND
    Publication number: 20240308974
    Abstract: The present invention relates to a compound of formula (I) wherein R1, R2, and R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a radiolabeled ligand.
    Type: Application
    Filed: May 21, 2024
    Publication date: September 19, 2024
    Inventors: Simon M. Ametamey, Luca Gobbi, Uwe Grether, Julian Kretz, Dieter Muri, Ahmed Haider Wahauib
  • Pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
    Patent number: 12071420
    Abstract: The invention relates to a compound of formula (I) wherein A1, A2, X and R1-R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: August 27, 2024
    Assignees: HOFFMANN-LA ROCHE INC., ETH ZUERICH
    Inventors: Luca Gobbi, Uwe Grether, Julian Kretz, Simon M. Ametamey
  • Radiolabeled cannabinoid receptor 2 ligand
    Patent number: 11999710
    Abstract: The present invention relates to a compound of formula (I) wherein R1, R2, and R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a radiolabeled ligand.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: June 4, 2024
    Assignees: HOFFMANN-LA ROCHE INC., ETH ZUERICH
    Inventors: Simon M. Ametamey, Luca Gobbi, Uwe Grether, Julian Kretz, Dieter Muri, Ahmed Haider Wahauib
  • Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists
    Patent number: 11655243
    Abstract: The invention relates to a compound of formula (I) wherein A1, A2 and R1-R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: May 23, 2023
    Assignees: HOFFMANN-LA ROCHE INC., EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
    Inventors: Simon M. Ametamey, Kenneth Atz, Luca Gobbi, Uwe Grether, Wolfgang Guba, Julian Kretz
  • NOVEL AZETIDINE-SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF CANNABINOID RECEPTOR 2
    Publication number: 20210130334
    Abstract: The invention relates to a compound of formula (I) wherein A1 and R1-R4 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 17, 2020
    Publication date: May 6, 2021
    Applicants: HOFFMANN-LA ROCHE INC., EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
    Inventors: Simon M. Ametamey, Luca Gobbi, Uwe Grether, Julian Kretz
  • NOVEL PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF CANNABINOID RECEPTOR 2
    Publication number: 20210115011
    Abstract: The invention relates to a compound of formula (I) wherein A1, A2, X and R1-R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 17, 2020
    Publication date: April 22, 2021
    Applicants: HOFFMANN-LA ROCHE INC., ETH ZUERICH
    Inventors: Luca Gobbi, Uwe Grether, Julian Kretz, Simon M. Ametamey
  • RADIOLABELED CANNABINOID RECEPTOR 2 LIGAND
    Publication number: 20210115012
    Abstract: The present invention relates to a compound of formula (I) wherein R1, R2, and R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a radiolabeled ligand.
    Type: Application
    Filed: December 17, 2020
    Publication date: April 22, 2021
    Applicants: HOFFMANN-LA ROCHE INC., ETH ZUERICH
    Inventors: Simon M. Ametamey, Luca Gobbi, Uwe Grether, Julian Kretz, Dieter Muri, Ahmed Haider Wahauib
  • PYRIDINE AND PYRAZINE DERIVATIVES AS PREFERENTIAL CANNABINOID 2 AGONISTS
    Publication number: 20210115027
    Abstract: The invention relates to a compound of formula (I) wherein A1, A2 and R1-R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 17, 2020
    Publication date: April 22, 2021
    Applicants: HOFFMANN-LA ROCHE INC., EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
    Inventors: Simon M. Ametamey, Kenneth Atz, Luca Gobbi, Uwe Grether, Wolfgang Guba, Julian Kretz
  • Radiolabeled cannabinoid receptor 2 ligand
    Patent number: 10227308
    Abstract: The present invention relates to a compound of formula (I) wherein R1 is defined as in the description and in the claims. The compound of formula (I) can be used as radiolabeled ligand.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: March 12, 2019
    Assignees: HOFFMANN-LA ROCHE INC., EIDGENÖSSISCHE TECHNISCHE HOCHSCHULE ZÜRCIH, UNIVERSITÄT ZÜRICH
    Inventors: Simon M. Ametamey, Juergen Fingerle, Luca Gobbi, Uwe Grether, Ahmed Haider, Thomas Hartung, Linjing Mu, Leo Nicholls, Mark Rogers-Evans, Christoph Ullmer
  • BENZAZEPIN-1-OL-DERIVED PET LIGANDS WITH HIGH IN VIVO NMDA SPECIFICITY
    Publication number: 20170224852
    Abstract: The present invention is directed to benzazepin-1-ol-derived compounds for use in the diagnosis of NMDA receptor-associated diseases or disorders by positron emission tomography (PET). The invention also relates to a method for the diagnosis of NMDA-receptor-associated diseases or disorders by administering to a patient in need of such diagnosis a radioactively labelled compound of the invention in an amount effective for PET imaging of NMDA receptors, recording at least one PET scan, and diagnosing an NMDA-receptor-associated disease or disorder from an abnormal NMDA receptor expression pattern on the PET scan. NMDA-receptor-associated diseases or disorders that can be diagnosed with the radioactively labelled benzazepin-1-ol-derived compounds include but are not limited to neurodegenerative diseases or disorders, Alzheimer's disease, depressive disorders, Parkinson's disease, traumatic brain injury, stroke, migraine, alcohol withdrawal and chronic and neuropathic pain.
    Type: Application
    Filed: February 8, 2017
    Publication date: August 10, 2017
    Inventors: Simon M. Ametamey, Stefanie Kraemer, Ahmed Haider, Linjing Mu, Bernhard Wuensch
  • 4-OXO-1, 4-DIHYDROQUINOLINE-3-CARBOXAMIDE AS SELECTIVE LIGAND FOR CANNABINOID RECEPTOR 2 FOR DIAGNOSIS AND THERAPY
    Publication number: 20170174632
    Abstract: The present invention is directed to new compounds selectively binding the cannabinoid 2 receptor. In addition, the invention relates to the use of said compounds for determining cannabinoid receptor 2 (CB2)-selective receptor localization and density, preferably in the central nervous system (CNS), the peripheral nervous system (PNS), heart, liver, gastrointestinal tract, spleen, pancreas, kidney, testis, ovary and/or the prostate. Moreover, the invention pertains to the use of said compounds in the diagnosis, prophylaxis and/or therapy of CB2 receptor-related diseases.
    Type: Application
    Filed: July 8, 2015
    Publication date: June 22, 2017
    Inventors: Simon M. Ametamey, Roger Slavik, Linjing Mu
  • RADIOLABELED CANNABINOID RECEPTOR 2 LIGAND
    Publication number: 20170166534
    Abstract: The present invention relates to a compound of formula (I) wherein R1 is defined as in the description and in the claims. The compound of formula (I) can be used as radiolabeled ligand.
    Type: Application
    Filed: February 27, 2017
    Publication date: June 15, 2017
    Applicants: Hoffmann-La Roche Inc., EIDGENÖSSISCHE TECHNISCHE HOCHSCHULE ZÜRICH, UNIVERSITÄT ZÜRICH
    Inventors: Simon M. Ametamey, Juergen Fingerle, Luca Gobbi, Uwe Grether, Ahmed Haider, Thomas Hartung, Linjing Mu, Leo Nicholls, Mark Rogers-Evans, Christoph Ullmer